StockNews.com began coverage on shares of 22nd Century Group (NASDAQ:XXII – Get Free Report) in a research note issued on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.
22nd Century Group Price Performance
Shares of NASDAQ XXII opened at $0.10 on Wednesday. 22nd Century Group has a 1 year low of $0.09 and a 1 year high of $6.56. The stock has a market capitalization of $4.66 million, a P/E ratio of 0.00 and a beta of 1.45. The company’s 50-day moving average is $0.19 and its 200 day moving average is $0.64.
22nd Century Group (NASDAQ:XXII – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.36) earnings per share for the quarter. The firm had revenue of $7.95 million for the quarter. 22nd Century Group had a negative net margin of 275.12% and a negative return on equity of 380.39%.
Hedge Funds Weigh In On 22nd Century Group
About 22nd Century Group
22nd Century Group, Inc, a tobacco products company, engages in the sale and distribution of its own proprietary new reduced nicotine tobacco products. The company offers reduced nicotine content tobacco plants and very low nicotine combustible cigarette products. It also provides contract manufacturing services for conventional combustible tobacco products for third-party brands.
Featured Stories
- Five stocks we like better than 22nd Century Group
- About the Markup Calculator
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- Bank Stocks – Best Bank Stocks to Invest In
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.